Anyone with rare and neurological disease can relate: there aren’t a ton of treatment options and there are almost never any cures for our conditions. We often times just have to treat the symptoms, instead of the root of the problem, like putting on a band-aid.
So when the possibility of treatment arises, our hopes get high! And today is a good day for hope in the Duchenne Muscular Dystrophy (DMD) world.
According to this Business Wire press release, Catabasis Pharmaceuticals, Inc. and Muscular Dystrophy Association (MDA) announced a collaboration that will enable the execution of Part B of the MoveDMD clinical trial of CAT-1004.
CAT-1004 is an oral medication that could be reduce muscle deterioration and possibly increase muscle regeneration in those with DMD, regardless of the underlying dystrophin mutation. So far, trials with animals have been promising.
Additionally, Part A of the clinical trial (which only includes boys with DMD), has proven positive results in terms of safety!
This could mean great things in the long-run for those suffering with DMD. This treatment wouldn’t just be a band-aid– it would be the healing cream for the large cut that is Duchenne Muscular Dystrophy.
